Abcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedSV
Sanofi Ventures
Activity from announced rounds
Activity in this selectionOct 16, 2026 · Jul 19, 2026
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $201M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionEpicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedQuantHealth
AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment
$45MSeries B
Role not disclosed